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Antiretroviral-based strategies for HIV prevention have shown inconsistent results in women.
We investigated whether vaginal microbiota modulated tenofovir gel microbicide efficacy
in the CAPRISA (Centre for the AIDS Program of Research in South Africa) 004 trial.Twomajor
vaginal bacterial community types—one dominated by Lactobacillus (59.2%) and the other
where Gardnerella vaginalis predominated with other anaerobic bacteria (40.8%)—were
identified in 688 women profiled.Tenofovir reduced HIV incidence by 61% (P = 0.013) in
Lactobacillus-dominant women but only 18% (P = 0.644) in women with non-Lactobacillus
bacteria, a threefold difference in efficacy. Detectible mucosal tenofovir was lower in
non-Lactobacilluswomen, negatively correlating with G. vaginalis and other anaerobic bacteria,
which depleted tenofovir by metabolism more rapidly than target cells convert to
pharmacologically active drug.This study provides evidence linking vaginal bacteria to
microbicide efficacy through tenofovir depletion via bacterial metabolism.
M
ore than 1 million women are infected
with HIV annually, and the majority of
these new infections occur in youngwom-
en in sub-SaharanAfrica, with SouthAfrica
having among the highest incidence rates
(1, 2). Antiretroviral-based clinical trials inmen
who have sex with men have consistently dem-
onstrated effectiveness in preventingHIV infection
(3–5); however, studies in women have produced
widely varying results. In clinical trials of women,
the efficacy of antiretroviral drugs to prevent HIV
infection ranged from –49% [VOICE (Vaginal and
Oral Interventions toControl theEpidemic) study]
to 75% [TDF2 (Tenofovir Disoproxil Fumarate
Two) study] for daily oral tenofovir or tenofovir-
emtricitabine and from 0% [FACTS (Follow-on
African Consortium for Tenofovir Studies) 001]
to 39% [CAPRISA (Centre for the AIDS Program
of Research in South Africa) 004] for daily or co-
ital vaginally-applied tenofovir gel (fig. S1). Var-
iability in the levels of adherence (6) has been
shown to be a major contributing factor for the
diverse trial outcomes in women. However, little
is known about what biological factors may also
contribute to the variability in these results andwhy
higher adherence is required for antiretroviral-
based prevention efficacy in women (7).
The vaginal compartment contains many mi-
crobial species critical for the health of the vaginal
mucosa, and dysbiosis of vaginal bacteria, clin-
ically known as bacterial vaginosis (BV), can re-
sult in negative reproductive health outcomes
(8, 9). The recent advent of advancedmolecular
tools has redefined our understanding of vagi-
nal bacteria communities (10, 11), where the
most frequently observed community state types
(CSTs) have been described (11–14). Although
substantial heterogeneity exists, a key com-
monality is that CSTs fall into two clear groups:
(i)Lactobacillus-dominant, where one ormore spe-
cies of Lactobacillus make up >90% of the to-
tal copy number or sequencing reads (L. iners,
L. crispatus, L. jensenii, and L. gasseri), and (ii)
non–Lactobacillus-dominant, with Lactobacillus
making up <30% of the total copy number or se-
quencing reads. The non–Lactobacillus-dominant
group typically contains a high abundance of
Gardnerella vaginalis alone or codominant with
other facultative and obligate anaerobic bacte-
ria, including Prevotella ssp., Mobiluncus ssp.,
and/or severalClostridia species. BV occurs after
a shift from Lactobacillus dominance to these
more diverse communities (11, 12), is frequently
asymptomatic, and can often go undetected using
traditionalAmsel’s criteria (15) and/or theNugent’s
score used to diagnose BV (16).
Bacterial vaginosis is associated with poor re-
productive health outcomes and increased HIV
infection risk in women (17 ), by as much as 60%
in some meta-analyses of women with BV (18).
BV likely increases HIV risk through multiple
mechanisms, including increased inflammation
and target cells, as well as vaginal epithelial bar-
rier disruption and wound-healing impairment;
however, themechanisms are not entirely under-
stood (13, 19, 20). Given that women from sub-
Saharan Africa have high prevalence rates of BV
(21) and that HIV prevention strategies are being
targeted for women in these areas, we inves-
tigated whether vaginal microbial communities
may affect the efficacy of antiretroviral-based pre-
vention technologies, especially those that are
topically applied to the vaginal surface.
Characterization of the vaginal microbiome
using unbiasedmetagenomic,metatranscriptomic,
and metaproteomic approaches represents a po-
tential paradigm shift in understanding host-
microbial interactions at the mucosal surface
in vivo.We recently usedmetaproteomics to gain
insight into host-bacterial interactions in vaginal
microbial dysbiosis (20). This method simultane-
ously collects unbiased information onmicrobial
and host proteomes, thus providing systems-level
information onmicrobial communities andmuco-
sal surfaces not available with other techniques.
In this work, we used ametaproteomic approach
to assess whether vaginal bacteria modulate the
efficacy of the topical microbicide tenofovir in pre-
venting HIV infection, and we also used in vitro
systems to determinemechanisms of microbiome
influence on tenofovir.
Vaginal microbial diversity in
women using tenofovir or placebo
microbicide gels
Samples from 688HIV-negative women that were
assigned to either the tenofovir or the placebo-gel
armwere analyzed by proteinmass spectrometry,
as outlined in thematerials andmethods (fig. S2).
Proteomic analysis identified 3334 distinct bac-
terial proteins from 188 different species in the
cervicovaginal lavage (CVL) samples of 688women.
Two major vaginal bacterial community groups
were identified: one in which Lactobacillus was
the predominant genus (group I) (n = 423 wom-
en, 61.5%) and the other dominated by non-
Lactobacillus microbiota (group II) (n = 265
women, 38.5%) (Fig. 1). Approximately 11% of indi-
viduals hadno single dominant species (defined as
>50% community composition), and the majority
of these individuals fell into group II.
In comparing the mass spectrometry proteo-
mic approach with 16S ribosomal RNA (rRNA)
sequencing, we found concordancewith respect to
classifyingwomen into groups I and II (91.5%agree-
ment) and measurements of bacterial abundance,
including major taxa Lactobacillus, G. vaginalis,
Prevotella, and others (P < 0.001) (fig. S3). A lim-
itation of this study was that clinical BV data
was not collected during the CAPRISA 004 trial,
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thus precluding comparisons to Nugent score or
other BV criteria.
Group I showed the lowest diversity [Shannon
diversity index (H-index)median: 0.05], with the
majority (70.5%) having L. iners as the dominant
species, followed by L. crispatus (15.1%) and other
lactobacilli, such as L. jensenii and L. gasseri
(3.0%). In Fig. 1B, the first subgroup (a) was ho-
mogeneous, with clear dominance ofLactobacillus
(54.7%) with very low diversity (H-index median:
0.035), whereas a minority of these individuals
(subgroupb, 6.8%) showedan intermediate amount
of diversity (H-index median: 0.87) where small
amounts of G. vaginalis, Pseudomonas, and other
bacteria were detected. A subanalysis of group
Ia at theLactobacillus species level clearly illustrates
L. iners as predominant (fig. S4).
Women in group II had higher overall bacterial
diversity (H-index: 0.78) with several distinct sub-
groups. The largest subgroup (c) was dominated
byG. vaginalis (n= 163, 23.7%,H-index: 0.66) and
containedmultiple taxa, including Prevotella and
minor amounts of Lactobacillus andMobiluncus
(Fig. 1B). The second-largest subgroup (d) was
themost diverse andhadno one clearly dominant
taxa (n = 78, 11.3%, H-index: 1.15); G. vaginalis,
Prevotella, andMobiluncuswere predominant.
Finally, the smallest subgroup (e) was low in diver-
sity, containing eitherPseudomonasorEscherichia
(n = 24, 3.5%, H-index: 0.14) (Fig. 1B). Grouping
subgroups a and b, which showed relative homo-
geneity in a single group (group I), with the re-
maining three subgroups (c, d, and e), which had
more variability and diversity into a single group
(group II), was supported by principal components
analysis (Fig. 1C). Overall, themajority (96.2%,n=
407) of women in group I had >50% Lactobacillus
by abundance.
For downstream comparisons of topical teno-
fovir efficacy, we chose a Lactobacillus-dominant
(>50%) (LD) or non–Lactobacillus-dominant (≤50%)
(non-LD) classification, as >50% Lactobacillus at
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Fig. 1. Bacterial profiling by mass spectrometry using cervicovaginal lavage samples from 688 women from the CAPRISA 004 trial. (A) Overall
bacterial diversity plot of the major genera of all women profiled. (B) Average bacterial community group structure for each of the two major profiles: group I
(subgroups a and b) and group II (subgroups c, d, and e). (C) Principal components analysis of 688 women using bacterial proportion data showing the
five subgroups.
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the proteome level corresponds with a practical
clinical marker of vaginal pH below 4.5 [inter-
quartile range pH value of 4.0 to 4.5 (20)] and
accurately identified 96.2% of group I individuals.
The use of LD and non-LD definitions did not
appreciably change any outcomes reported on
the basis of group I versus group II comparisons.
Both LD and non-LD women had similar base-
line clinical, behavioral, and demographic char-
acteristics, as well as sexual behavior and gel
adherence during the trial (table S1). The presence
of a sexually transmitted infection (STI)—which
included Chlamydia trachomatis, Trichomonas
vaginalis, Neisseria gonorrhea,Mycoplasma gen-
italium,Treponemapallidum, andherpes simplex
virus 2 (HSV-2)—was comparable betweengroups.
Althoughnot statistically significant,womenwithin
the non-LDgroupweremarginally younger (mean
age 23.6 versus 24.1 years, P=0.092).Within each
of the groups of LD and non-LDwomen, the num-
ber of individuals assigned to tenofovir gel and
placebo gel was similar (table S2).
Vaginal microbial profiles and tenofovir
gel efficacy
In the LD group, the HIV incidence rate was 61%
lower [95% confidence interval (CI): 0.16 to 0.89]
inwomen assigned to tenofovir gel comparedwith
those assigned to the placebo gel [2.7 versus 6.9
per 100 women-years (where 1 woman-year is de-
fined as 1 year of study observation of onewoman);
incidence rate ratio (IRR) = 0.39; P = 0.013]
(Fig. 2A). In contrast, in non-LDwomen, the HIV
incidence rate was only 18% lower (95% CI: 0.37
to 1.77) in those assigned to tenofovir gel compared
with those assigned to placebo gel (6.4 versus 7.8
per 100 women-years; IRR = 0.82; P = 0.644) (Fig.
2B). Adjusting for STIs (including HSV-2 infec-
tion), antibiotic usage, depotmedroxyprogesterone
acetate (DMPA) usage, and sexual behaviors (fre-
quency of sex, number of partners, and condom
usage) did not affect these findings (table S3).
Lactobacillus, particularly L. crispatus, has been
associated with reduced HIV infection. Although
the HIV incidence rate of 4.8 per 100 women-
years in LD women was 32% lower (95% CI: 0.4
to 1.12) than the 7.1 per 100 women-years in non-
LDwomen, this was not statistically significant
(P = 0.127) (fig. S5). Comparing the subgroup
of all 63 L. crispatus–dominant (>50% abun-
dance) to non-LD women yielded a 57% lower
HIV incidence (95% CI: 0.13 to 1.41) that was
not statistically significant (3.1 versus 7.1 per
100 women-years; P = 0.167) (fig. S6). Comparison
ofL. crispatus–dominantwomen to all others as a
single group (L. iners–dominant and non-LD
women) produced similar findings (50% lower
HIV incidence; 3.1 versus 6.0 per 100 women-
years; 95% CI: 0.16 to 1.60, P = 0.237). Similarly,
within the placebo group, the 31 L. crispatus–
dominantwomen comparedwithnon-LDwomen
showed a 48% lower HIV incidence (95% CI: 0.12
to 1.27) that was not statistically significant (4.17
versus 7.8 per 100women-years; P=0.387) (fig. S7).
This is likely attributed to insufficient power due
to the low numbers of women with L. crispatus
dominance. However, because the proportion of
women with L. crispatus dominance was similar
in women assigned to tenofovir gel and placebo
gel (51% versus 49%), the HIV incidence differ-
ences between these two groups of women are
not due to L. crispatus. In addition, considering
just L. iners–dominant women, the efficacy of ten-
ofovir was maintained, where the HIV incidence
ratewas 67% lower (95%CI: 0.13 to 0.83) in those
assigned to tenofovir gel compared with those
assigned to placebo gel (2.5 versus 7.7 per 100
women-years in the tenofovir and placebo arms,
respectively; P = 0.0118) (fig. S8).
Microbicide gel adherence and tenofovir
efficacy in LD and non-LD women
Gel adherence, as assessed by monthly empty
applicator returns (22), was similar in both groups:
60.0% [244 of 407 (244/407)] of LD women
compared to 61.4% (172/280) of non-LD women
had >50% gel adherence (where >50% of sex acts
were covered by two applications of the gel, as
recommended in the trial) (Table 1). Stratifying
LD and non-LD women separately on adherence
demonstrates that gel adherence >50% was as-
sociated with higher efficacy in preventing HIV
in LD women than in non-LD women (Table 1).
The efficacy of tenofovir gel in preventing HIV
infection in the subgroup of women with >50%
adherencewas 78% (95%CI: 29%, 95%; P= 0.003)
in the LD group but only 26% (95% CI: –98%,
73%; P = 0.558) in the non-LD group.
Vaginal tenofovir concentrations are
lower in non-LD versus LD women
Tenofovir concentrations (n= 270) were assessed
in a random sample of CVLs from HIV-negative
women and from the first postinfection visit CVL
fromHIV seroconvertors. Although gel adherence
was not different between the LD and non-LD
groups and time since the last gel application was
similar (P = 0.558) (table S1), tenofovir was only
detectable in CVL samples in 29.8% (34/114) of
non-LDwomen comparedwith 46.2% (72/156) of
LD women (P = 0.008). Genital tenofovir con-
centrations were also significantly lower in non-
LD (upper quartile = 24.3 ng/ml) compared
with LD women (upper quartile = 8020 ng/ml)
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Fig. 2. Cumulative HIV infection probability by treatment assignment in women with vaginal Lactobacillus dominance and non-Lactobacillus
bacterial dominance. Data for (A) Lactobacillus-dominant (Lactobacillus > 50%) (n = 407) and (B) non–Lactobacillus-dominant (Lactobacillus ≤ 50%)
(n = 281) women. The tables below each panel show the cumulative number of HIV infections in each study arm, corresponding HIV incidence rates, and
efficacy of tenofovir gel to prevent HIV acquisition for each additional 6 months of follow-up. The protective efficacy of tenofovir gel was more than threefold
higher in women with Lactobacillus dominance (A) compared with non-Lactobacillus dominance (B). HR, hazard ratio.
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(P = 0.0077). A subanalysis showed that genital
tenofovir concentrations negatively correlated
withG. vaginalis protein abundance (correlation
coefficient r = –0.19, P = 0.0014) and other an-
aerobic bacteria (Prevotella, r= –0.14,P = 0.023),
suggesting a relationship between BV-associated
bacteria and tenofovir levels.
Metabolism by G. vaginalis and
BV-associated bacteria leads
to tenofovir depletion
Given the decreased levels of mucosal tenofovir
in non–LD-dominant women with G. vaginalis
and other BV-associated bacteria versus LDwom-
en, we aimed to determine whether interactions
between microbes and tenofovir may underlie
altered drug levels. We used an in vitro culture
system to assess potential biodegradation of ten-
ofovir by the major bacterial species present in
this cohort. We found that tenofovir concentra-
tions in culture with G. vaginalis decreased
rapidly by 50.6%comparedwithmarginal changes
in either L. iners (P = 0.0037), L. crispatus (P =
0.0019), or abiotic (same NYCIII media without
bacteria) control (P < 0.0001) at 4 hours (Fig. 3A).
The differential decline continued; by 24 hours,
tenofovir concentrations in the culture medium
had dropped 67.4% with G. vaginalis but only
14.0% with L. iners (P < 0.0001) and 9.4% with
L. crispatus (P < 0.0001) (Fig. 3A). Of interest,
G. vaginalis used here was a subtype C strain
(ATCC type strain 14018), but repeating these
methods with G. vaginaliswith Kenyan clinical
isolates from three different subtypes demon-
strated that all subtypes of G. vaginalis metab-
olized tenofovir (P<0.005) (fig. S9). Concomitantly
to tenofovir loss, intracellular tenofovir concen-
trations rose sharply in G. vaginalis but not in
L. iners or L. crispatus cultures (P < 0.0001) (Fig.
3B). Predicted metabolites at mass/charge ratios
(m/z) of 136.06, 206.10, 159.07, and 59.05 showed
a sharp increase at 136.06 m/z in G. vaginalis
cultures, indicating adenine production via cleav-
age of oxy-methylphosphonic acid (Fig. 3C), the
side-chain component of tenofovir (P < 0.0001
compared with L. crispatus, L. iners, and abi-
otic). Residual tenofovir plus the intracellular
metabolite adenine made up >80% of recovered
products, indicating that adenine is the major
metabolite of tenofovirmetabolismbyG. vaginalis
(Fig. 3D). Finally, to determine whether other
major bacterial species in non-LD women were
capable of metabolizing tenofovir, we tested the
ability of P. amnii, P. bivia,Mobiluncusmulieris,
andEscherichia coli to deplete tenofovir.We found
that both Prevotella species and M. mulieris sig-
nificantly depleted tenofovir compared with abi-
otic (Wilkins-Chalgrenmedia) controls (P=0.0007
for all at 24 hours), and E. coli trended toward
depletion (P=0.100 as compared to abiotic tryptic
soy media), though not to the same extent or as
rapidly as G. vaginalis (Fig. 3E).
Metabolism by vaginal bacteria affects
uptake and conversion of tenofovir to
active drug in target cells
We next assessed whether tenofovir metabolism
by bacteria affects the kinetics or ability of target
cells to uptake tenofovir and convert to pharma-
cologically active tenofovir diphosphate. We per-
formed cocultures of Jurkat cells (HIV targets) in
the presence of tenofovir, with G. vaginalis,
L. iners, L. crispatus, or abiotic controls (both
tenofovir alone or tenofovir plus Jurkat cells),
to assess overall tenofovir depletion and uptake in
culture. In these Jurkat cell cultures,we found that
tenofovir is most rapidly depleted in the presence
ofG. vaginalis, relative to Jurkat cells alone (P =
0.0001) or those with L. iners (P = 0.0022) or
L. crispatus (P = 0.0238) (Fig. 4A). To assess mi-
crobial tenofovir metabolism, we measured ade-
nine levels in the cell pellets and found that adenine
was created only in cultures with G. vaginalis
(P = 0.0022 relative to all conditions) (Fig. 4B). A
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Fig. 3. Metabolism of tenofovir by G. vaginalis and BV-associated
bacteria. (A) Tenofovir fold change in supernatants after 1 mg/ml tenofovir
was added to G. vaginalis, L. iners, and L. crispatus cultures or abiotic
controls in NYCIII media. Tenofovir levels were measured by mass
spectrometry at 0, 4 and 24 hours. Data show average ± SEM (error bars)
of 18 replicate experiments for L. iners and G. vaginalis cultures compared
with 15 replicates of abiotic controls. (B) Total intracellular tenofovir
detected in cell pellets from cultures. (C) Predicted tenofovir metabolite
adenine was measured in cultures. (D) Total drug recovery of tenofovir
and adenine metabolite. (E) Tenofovir fold change in supernatants
after 1 mg/ml tenofovir was added to cultures of P. amnii, P. bivia,
M. mulieris, E. coli, or abiotic controls in Wilkins-Chalgren (WC) media
or tryptic soy (TS) broth (for E. coli). Data show average ± SEM of six
replicate experiments for P. amnii, P. bivia, and M. mulieris and four
replicates for E. coli, compared with five replicate abiotic controls.
P values are calculated by Mann-Whitney U test. ns, not significant.
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critical component is whether G. vaginalis can
metabolize tenofovir more rapidly than target
cells can convert tenofovir to pharmacologically
active tenofovir diphosphate. To assess this, we
measured tenofovir diphosphate in cell pellets
and found that although tenofovir diphosphate
was made at equal levels in Jurkat cells alone and
the presence of Lactobacillus spp., it was signifi-
cantly decreased in the presence of G. vaginalis
(P = 0.0002, P = 0.0022, and P = 0.0238 relative
to tenofovir + Jurkat alone, tenofovir + Jurkat +
L. iners, or tenofovir + Jurkat + L. crispatus, re-
spectively) (Fig. 4C). Total drug recovery mea-
surements (tenofovir + tenofovir diphosphate +
adenine) demonstrated that all components of
tenofovir were fully recovered (Fig. 4D). These
data demonstrate thatG. vaginalis is capable of
decreasing pharmacologically active tenofovir di-
phosphate bymetabolizing tenofovir before drug
uptake by target cells.
Implications for antiretroviral-based
HIV prevention
The efficacy of tenofovir-containing topicalmicro-
bicide to prevent HIV infection varied more than
threefold depending on vaginal bacterial profiles;
tenofovir gel reducedHIV incidence by 61% in LD
women but only by 18% in non-LDwomen. These
efficacy differences betweenLDandnon-LDwom-
en were consistently present in the most gel-
adherent women (78% versus 26%), as well as
in the least adherent women (17% versus 4%).
In vitro studies demonstrated that metabolism of
tenofovir occurredbyG.vaginalis,P. bivia,P. amnii,
andM. mulieris, and slightly by E. coli, but not
by L. iners or L. crispatus, indicating a putative
mechanism for the observed differences in topi-
cal microbicide efficacy. The modifying effect of
Lactobacillus dominance on tenofovir gel efficacy
underscores the importance of both high adherence
and LD vaginal bacterial communities for women
to benefitmaximally from topicalmicrobicides for
HIV prevention.
In searching for an underlying cause for the
discordance between applicator adherence and
detectable vaginal tenofovir concentrations be-
tween the LD and non-LD groups, we found that
non–Lactobacillus-dominant bacteria associated
with BV rapidly metabolized tenofovir, thereby
likely reducing extracellular drug availability. The
rapid loss of tenofovir by G. vaginalis and other
bacteria may also affect gel adherence estimates
based on vaginal drug levels in non-LD women,
particularly considering that Gardnerellametab-
olizes tenofovir more rapidly than target cells
uptake and convert the drug to active form. Thus,
although adherence is important for efficacy
(23, 24), the lack of Lactobacillus dominance
may also be a contributing factor. These data
indicate that women with BV may have to be
more rigorous in their adherence to tenofovir
gel administration to be protected against HIV
infection, due to the rapidmetabolism of tenofovir
by dysbiotic bacteria. Because of the potential in-
terplay between vaginal bacteria and adherence
in topicalmicrobicide efficacy, a useful next step
could be to evaluate the proportion of non-LD
women in other topical microbicide trials of
tenofovir conducted in Africa such as VOICE and
FACTS (23, 24). These findingsmay have broader
implications for other topical antiretroviral deliv-
ery strategies, such as vaginal rings, for tenofovir-
based HIV prevention.
The prevalence of Lactobacillus dominance in
women in CAPRISA 004 (59%) was comparable
to that observed in self-described black women
from a North American study (58%) (12) but con-
siderably lower than that reported in Caucasian
women (90%).However, the extent ofLactobacillus
dominance may differ even within the same
country or region. The Lactobacillus species and
overall CSTs in our study participants were sim-
ilar to those described in a previous South African
study (13, 25) but somewhat different from those
reported recently by the FRESH (Females Ris-
ing through Education, Support, and Health) co-
hort in KwaZulu-Natal in South Africa (13). The
reasons for these differences in the prevalence of
Lactobacillus dominance are not known. Some
notable differences were that the CAPRISA 004
womenwere slightly older (24 versus 21 years) and
had higher hormonal contraceptive usage (97%
versus 54% on DMPA, norethisterone oenan-
thate, or combined oral contraceptive pill), both
of which have previously been associated with
higher Lactobacillus (26, 27).
Although Lactobacillus has been associated
with lower HIV incidence in previous observa-
tional studies, we did not find a strong relation-
ship between LD status and HIV protection in
the placebo arm. Thismay be due to the predom-
inance of L. iners in the women in our study,
rather than L. crispatus, which has been associ-
ated with lower HIV incidence (19, 28) [whereas
L. iners has been associated with increased HIV
risk (29)], or simply being underpowered with
few L. crispatus–dominant women. Nevertheless,
we did observe a nonsignificant trend of reduced
HIV incidencewithL. crispatus–dominantwomen
comparedwithwomenwho had non–Lactobacillus-
dominant profiles, regardless of tenofovir or placebo
gel assignment.
The ecological diversity in the vaginal micro-
biome has been previously linked to changes in
mucosal immunity in the female genital tract,
including elevated cytokine levels, increased
HIV target cells (CD4+CCR5+ T cells), as well as
epithelial barrier disruption (20, 30, 31). Thus,
the presence of BV-associated inflammatory bac-
teria could have influences at the vaginal mucosa
thatmay add collectively to amultifactorialmech-
anism affectingmicrobicide efficacy. The relative
contributions of drug depletion and these po-
tential host modulatory effects on microbicide
efficacy would be an important avenue of future
investigation.
Some limitations need to be taken into ac-
count when interpreting these data. The lack of
clinical BV measurements, such as Nugent score
or Amsel’s criteria, precludes our ability to associate
these findings with clinical BV criteria, an im-
portant factor in vaginal health. Instead, these
data are limited to associations with metapro-
teomic and metagenomic characterization of
BV. Another caveat of this study is the assumption
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Table 1. Effect of adherence on the HIV prevention efficacy of 1% tenofovir gel in women participating in the CAPRISA 004 trial, stratified by
Lactobacillus dominance in the female genital tract. One woman did not produce adherence data. n, number of women.
No. of HIV infections/women-years HIV incidence (95% CI)
Gel adherence Tenofovir Placebo n Tenofovir Placebo Incidence rate ratio Efficacy P value (log-rank)
All participants
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ...
Lactobacillus-dominant 9/331 22/318 407 2.7 (1.2; 5.2) 6.9 (4.3; 10.5) 0.39 (0.16; 0.89) 61% 0.013
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ...
Non–Lactobacillus-dominant 14/219 17/218 281 6.4 (3.5; 10.7) 7.8 (4.5; 12.5) 0.82 (0.37; 1.77) 18% 0.644
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ...
Greater than 50% adherence 13/349 26/304 416 3.7 (2.0; 6.4) 8.6 (5.6; 12.5) 0.44 (0.21; 0.88) 56% 0.013
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ...
Less than 50% adherence 10/200 13/232 271 5.0 (2.4; 9.2) 5.6 (3.0; 9.6) 0.89 (0.35; 2.21) 11% 0.771
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ...
Lactobacillus-dominant
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ...
Greater than 50% adherence 4/209 15/176 244 1.9 (0.5; 4.9) 8.5 (4.8; 14.1) 0.22 (0.05; 0.71) 78% 0.003
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ...
Less than 50% adherence 5/122 7/142 163 4.1 (1.3; 9.6) 4.9 (2.0; 10.2) 0.83 (0.21; 3.05) 17% 0.735
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ...
Non–Lactobacillus-dominant
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ...
Greater than 50% adherence 9/141 11/128 172 6.4 (2.9; 12.2) 8.6 (4.3; 15.4) 0.74 (0.27; 1.98) 26% 0.558
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ...
Less than 50% adherence 5/78 6/90 108 6.4 (2.1; 15.0) 6.7 (2.4; 14.5) 0.96 (0.23; 3.79) 4% 0.935
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ...
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that a single random sample represents the
vaginal microbiome for the duration of the trial.
Previous longitudinal evaluations of women dem-
onstrated that some bacterial communities shift
substantially in short periods of time, whereas
others, including those dominated by Lactobacillus
species, demonstrated considerably more sta-
bility, where outgrowth of anaerobic bacteria
was less frequent (~10%) over time (32). In a
sensitivity analysis to address this question,
unrealistically high levels of misclassification
would be required to double the HIV incidence
rate observed in this study. In randomly selected
LD women (n = 21), 76% maintained LD status
at previous visits (median days = 301), and a
24%misclassification had aminimal effect on the
overall incidence rate. Further, as neither the trial
participants nor investigators were aware of LD
status at randomization, overall random alloca-
tion in the CAPRISA 004 trial is expected to lead
to comparable groups assigned to studyarmsof the
LD and non-LD strata.
Although it is a limitation of the data that the
metabolism of tenofovir was only demonstrated
in vitro here, the decreased tenofovir levels in
women with vaginal dysbiosis support this as
a potential in vivo mechanism. Further, the
in vitro studies were performed with a range
from 1 to 10mg/ml, representing predicted in vivo
tenofovir concentrations after gel use (33), and
we observed similar kinetics of tenofovir metab-
olism despite tenofovir concentration. Because
multiple BV-associated bacteria could biodegrade
tenofovir in vitro, future studies assessing the ef-
fects of mixed bacteria cultures on tenofovir me-
tabolismwould be an important next step. Though
we have not yet assessed whether Pseudomonas
species metabolize tenofovir, they (group IIe)
represent a small fraction of women (3.5%), and
removal of this group in LD versus non-LD com-
parisons did not affect the reported outcomes.
Other BV-associated bacteria not evaluated in
this study may also metabolize tenofovir and
would be important to explore. We demonstra-
ted that clinical isolates of G. vaginalis are also
capable of degrading tenofovir, albeit at reduced
rates as compared with type strains, possibly due
to decreased growth rates in the clinical isolates.
In addition, this mechanism is supported by
several studies showing in vivo metabolism of
drugs by microbiota, just never in the context
of HIV infection and antiretroviral metabolism
(34). Furthermore, the kinetics of bacterial me-
tabolism of tenofovir relative to host cellular
uptake and conversion of tenofovir to the pharma-
cologically active phosphorylated form (tenofovir
diphosphate) demonstrated thatG. vaginalis can
actually metabolize tenofovir more rapidly that
target cells can convert it to tenofovir diphos-
phate. Previous studies in CAPRISA 004 demon-
strated that low levels of tenofovir diphosphate
were associatedwith infection (35), and a recent
study by Hillier et al. demonstrated that, in the
FAME study, both genital and plasma levels of
tenofovir diphosphate were negatively correlated
with G. vaginalis levels in the vagina, as well as
markers of BV, demonstrating the clinical rele-
vance of our results (36).
This study usedmass spectrometry–based pro-
teomics, an emerging technology for the study of
mucosal systems, to characterize vaginal bacteria.
Both mass spectrometry and standard 16S rRNA
sequencing hadhigh concurrence in the classifica-
tionofLactobacillus-dominantprofiles. Therewere
some differences in the proportion of detected
taxa. Particularly, in mass spectrometry analysis,
the predominant genera—such as Lactobacillus,
Gardnerella, and Prevotella—more frequently
dominate the bacterial proteome load as com-
pared with 16S results, similar to previous ob-
servations (20). This could be due to sensitivity
differences as the proteome spans a larger dy-
namic range, posttranscriptional regulatorymech-
anisms that modulate protein translation from
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Fig. 4. Kinetics of tenofovir depletion by bacteria relative to
conversion to pharmacologically active tenofovir diphosphate. In vitro
cultures of Jurkat cells (“cells”) with tenofovir, cocultured with L. crispatus,
L. iners, or G. vaginalis. (A) Tenofovir (TFV) is rapidly decreased in
supernatants of cultures including Jurkat cells and most rapidly in cultures
with G. vaginalis. (B) The metabolite of bacterial metabolism of tenofovir,
adenine, is only formed in the presence of G. vaginalis. (C) Tenofovir
diphosphate (TFV-DP) is produced in Jurkat cells in the presence
of L. iners and L. crispatus but is significantly lower in the presence
of G. vaginalis. (D) Total drug recovery demonstrates that tenofovir,
tenofovir diphosphate, and adenine make up major tenofovir-based drug
recovery. Error bars indicate SEM. ns, not significant.
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genes, a reflection of greater diversity of meta-
bolic states, or divergence of functionality be-
tween the same taxa in different individuals or
CSTs. Future studies of the bacterial metaproteome
may provide further insights into in vivo microbial
systems.
We assessed whether LD and non-LD women
differed with respect to clinical symptoms asso-
ciated with STIs and found that reported vaginal
symptoms did not differ between LD and non-LD
women. This finding is concordant with other
descriptions suggesting that the presence of G.
vaginalis is often asymptomatic (11, 12), making
it unlikely that G. vaginalis led to behavioral
changes affecting gel use. Whereas previous
results showed that tenofovir is protective against
HSV-2 (37), our subanalysis did not find an effect
of Lactobacillus dominance on efficacy of teno-
fovir against HSV-2 acquisition. However, given
the many differences between HIV and HSV-2,
including the target cells in the genital tract and
the unknown levels required for protection in vivo,
it is challenging to compare these two infections in
this context. Future studies aimed at assessing
tenofovir in decreased HSV-2 infection relative
to vaginal microbiota will be very important.
Because Lactobacillus dominance corresponds
with a relatively low vaginal pH, typically below
4.5 (12), vaginal pH testing may be a pragmatic
approach to identify womenmost likely to benefit
from topical tenofovir-containing microbicides
and potentially other prevention strategies. How-
ever, current treatment strategies for BVmay not
be sufficiently efficacious (38), and better strat-
egies that can both deplete anaerobic bacteria and
support recolonization with Lactobacillusmay be
required. If validated in other trials, this could be
a compelling reason for integrating topical micro-
bicide implementation with sexual and repro-
ductive health services so that vaginal health
becomes an integral component of HIV preven-
tion approaches.
Conclusions
Vaginal microbiota modulated the efficacy of the
topical tenofovir microbicide in CAPRISA 004.
The rapid depletion of tenofovir by G. vaginalis
and other BV-associated anaerobic bacteria by
metabolism provides a biological mechanism
likely contributing to a multifactorial process,
including increased vaginal inflammation and
adherence, leading to varying levels of HIV
prevention efficacy observed across topicalmicro-
bicide trials. This suggests that womenwith non–
Lactobacillus-dominant vaginal bacteria may be
more sensitive to the timing of gel application
and adherence, whereas bacterial communities
with Lactobacillus dominance may facilitate an
environment more conducive to topical microbi-
cide efficacy. Thus, vaginal pH and/ormicrobiota
screening are interventions that can potentially
be added to topicalmicrobicide initiation to guide
and enhance prevention of HIV in women. These
findings provide evidence about the importance
of vaginal microbial communities on prevention
efficacy, which could help improve this HIV-
specific prevention strategy for women.
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organism could rapidly metabolize and thereby inactivate the drug.
 tended to predominate in the women for whom tenofovir was less effective, and the authors found that thevaginalis
Gardnerella-dominant vaginal microbiome as it was among other women. Lactobacillusas effective among those with a 
timesmicrobiome (see the Perspective by Tuddenham and Ghanem). In a clinical trial of 688 women, tenofovir was three 
 now show that tenofovir efficacy in women depends on the composition of the vaginalet al.not women. Klatt 
Tenofovir is a preexposure drug used to prevent HIV infection. In clinical trials, tenofovir was effective for men, but
Vaginal microbiome influences HIV acquisition
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